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Abstract 
 
Background: People with head and neck cancer (HNC) have higher comorbidity 
levels but it remains unclear if pre-treatment comorbidity is an independent 
prognosticator in HNC. 
 
Methods: Survival analyses were performed using data from participants in a UK 
multicentre cohort study with cancers of the oral cavity (n = 668), oropharynx (n = 
1,074) and larynx (n = 530). Survival analyses were incrementally adjusted for age, 
gender, marital status, income, education, stage, alcohol and smoking. 
 
Results: After adjusting for demographic, clinical and behavioural confounders, 
higher baseline comorbidity was associated with reduced overall survival (mild 
comorbidity HR 1.4, 95% CI 1.1, 1.7; moderate comorbidity HR 1.7, 95% CI 1.3, 2.2; 
severe comorbidity HR 2.8, 95% CI 1.9, 4.; p-trend<.001).  
 
Conclusions: Our findings suggest that comorbidity is an independent 
prognosticator for overall survival in HNC. Comorbid illnesses should be considered 
in the assessment and treatment planning of people with HNC. 
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Introduction 
 
Head and neck cancers (HNC) comprise a group of heterogeneous malignancies 
affecting the oral cavity, pharynx, larynx, paranasal sinuses, salivary glands and 
thyroid. Combined HNC is the sixth most common cancer in Europe (1). The disease 
has a poor prognosis with overall 5-year survival rates around 66% (2). 
 
Comorbidity, the presence of coexistent medical conditions that are unrelated to the 
index disease (3), may independently affect health outcomes. Higher comorbidity 
scores have been shown to be adversely associated with overall survival (OS) (3-7), 
choice of treatment modality (3, 4, 8) and treatment outcomes in HNC (5, 8-11). People 
with HNC tend to have a higher comorbidity burden compared to the general 
population (3, 6). This may partially be attributable to their engagement in adverse 
health behaviours such as smoking and high alcohol intake that increase the risk of 
the development of comorbid conditions as well as HNC.  
 
The classical risk factors for most HNCs, with exception of thyroid and salivary gland 
tumours, are smoking and to a lesser extent alcohol consumption. More recently, the 
oncogenic Human Papillomavirus (HPV) has been shown to play a role in the 
development of certain HNC subtypes, specifically oropharyngeal squamous cell 
carcinomas. HPV-positive HNCs differ from tobacco-related HPV-negative tumours 
in their clinical characteristics and risk factor profiles (4, 12, 13). HPV-positive cancers 
typically present as smaller tumours with more frequent lymph node involvement but 
better OS (13). These findings may be partially due to a more favourable risk factor 
profile. People with HPV-positive oropharyngeal tumours tend to be non-smokers, 
consume less alcohol, have a higher socioeconomic status and a lower comorbidity 
burden (4, 7, 12, 14).  
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Previous studies have examined the impact of comorbidities on outcomes in HNC (6, 
7, 14-16). However, no prospective study has been able to adjust for HPV status, 
behavioural and social variables in their study populations while stratifying for HNC 
sub-site in the same model. Hence there is insufficient evidence to conclude whether 
comorbidity burden at diagnosis is an independent prognostic indicator in people with 
HNC or whether it constitutes a surrogate marker for health risk behaviours (4, 7).  
 
Despite these limitations the evidence suggests that comorbidity may be a useful tool 
to help stratify people. Revised staging models that incorporate comorbidity index 
scores have been proposed (4, 7). These models suggest that comorbidity in 
combination with the traditional Tumour Node Metastases (TNM) stage may be more 
accurate in predicting survival and could play an important role in treatment planning.  
 
Using data from Head and Neck 5000, a large UK multi-centre prospective cohort 
study, we examined the relationship between comorbidity and outcomes in HNC. The 
objectives of this study were to analyse the relationship between comorbidity at 
diagnosis and OS before and after adjustment for confounders and at different sites. 
 
  
Page 4 of 28
John Wiley & Sons, Inc.
Head & Neck
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 5
Materials and Methods 
 
Study population 
We used data from Head and Neck 5000, a large UK-based clinical cohort study that 
enrolled 5,478 eligible participants of 11,158 eligible people with HNC between April 
2011 and December 2014 (17). Research nurses or another trained member of the 
research team obtained informed written consent from all participants prior to study 
enrolment(18). The South West – Frenchay Regional Ethics Committee granted full 
ethical approval (ref: 10/H0107/57) for Head and Neck 5000 in 2010. Additionally, the 
research and development departments of each participating NHS Trust approved 
the study. Study methods and recruitment rates have previously been described in 
detail (17, 18). For this study we included Caucasian participants with HNC of the oral 
cavity, oropharynx and larynx who were treated with curative intent (Figure 1).  
 
Comorbidity measure 
The Adult Comorbidity Evaluation 27 (ACE 27) (19) was used to collect comorbidity 
data at diagnosis. The presence and severity of medical comorbidities were 
extracted from medical notes by local research nurses and scored by clinicians. 
Newly diagnosed HNCs were excluded from the score. The final ACE 27 score was 
derived from the highest ranked comorbidity. Participants without comorbid 
conditions received a score of 0. Mild comorbidity was defined as an ACE 27 grade 
of 1. In cases where moderate decompensation (grade 2) was present in two or more 
conditions affecting different organ systems, a final grade of 3 (severe 
decompensation) was awarded. 
 
Measures of confounders 
Confounding variables were identified based on previously reported associations with 
both exposure (comorbidity) and outcome (survival).  Clinical information regarding 
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diagnosis including tumour sub-site (classified using the International Classification 
of Diseases (ICD) 10), clinical TNM stage and planned treatment modality was taken 
from participants’ medical records and pathology reports. A self-administered 
baseline questionnaire provided data on participants’ age, gender, marital status, 
education and annual total household income.  Health risk behaviours at diagnosis 
were recorded using self-report questionnaires. Smoking status was categorised as 
never, current or former smokers (previously smoked at least 100 cigarettes up until 
1 year before diagnosis).  Baseline alcohol consumption was quantified as none, 
moderate (men and women drinking < 14 units/week), hazardous (men consuming 
14 – 50 units/week; w men consuming 14 – 35 units/week) and harmful (men 
consuming > 50 units/week; women consuming > 35 units/week). HPV status was 
determined by serological testing for HPV16 E6 antibodies using a glutathione S-
transferase multiplex assay with a cut-off value of > 1000 Median Fluorescence 
Intensity units (20) at the German Cancer Research Centre (DKFZ, Heidelberg, 
Germany) as previously described (21).  
 
Outcome measure 
Study participants were flagged up with the UK Health and Social Care Information 
Centre for notification of date and cause of death. Survival time was measured from 
study enrolment until either death or the end of the most recent follow-up period. 
 
Statistical analysis 
Chi-squared tests were used to assess the univariate relationship between 
categorical variables and comorbidity. Unadjusted Kaplan-Meier graphs were plotted 
to estimate OS for each cancer site. Cox proportional hazards regression models 
were used to evaluate OS in multivariable analyses. Hazard ratios (HR) and 95% 
confidence intervals (CIs) were adjusted for known or suspected confounders. Using 
the previously described confounding variables, four a priori survival models were 
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incrementally fitted for each cancer site. Model 1 (Minimally adjusted) was adjusted 
for age and gender only. Model 2 (Clinical) included the same variables as Model 1 
and also adjusted for TNM stage, treatment modality, and cancer site. Model 3 
(Social) included all previously used variables plus marital status, annual household 
income and education. Finally, Model 4 (Behavioural) was an extension of Model 3 
with addition of smoking status and alcohol intake to the list of confounders. To test 
the proportional hazards assumption, scaled Schoenfeld residuals were applied. To 
investigate the association between HPV status and comorbidity stratified survival 
analyses were performed. Comorbidity was grouped into low (0-1) and high (>2) ACE 
27 scores to achieve a larger sample size for each category in HPV-stratified survival 
analyses. Similarly, treatment-stratified analyses were performed to examine the 
relationship between surgical and non-surgical treatment modalities and survival in 
people with different comorbidity burden. Surgical treatment was defined as surgery 
alone and surgery plus an adjunct therapy. Non-surgical treatment modalities 
consisted of chemoradiation and stand-alone radiotherapy. 
The Head and Neck 5000 dataset version 2.2 was used for this study. All statistical 
analyses were performed using Stata 14.0 (StataCorp. 2015. Stata Statistical 
Software: Release 14. College Station, TX, USA: StataCorp LP).  
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Results 
 
Distribution of comorbidity in the study population 
Complete data were available for 2,272 participants. HPV data were available for a 
subset of oropharyngeal cancer (n = 932). A total of 466 deaths were recorded in 
7167.9 person-years of follow-up. Mean follow-up time was 3.2 years (standard 
deviation 1.2). Table 1 shows the baseline characteristics of study participants by 
cancer site. Almost half (52.6%) of the participants had at least one medical condition 
at the time of diagnosis. Participants with oropharyngeal cancers were more likely to 
have no comorbidity (52.5%) compared to participants with oral cavity (45.5%) or 
laryngeal cancers (39.5%). HPV serology was available for 86.8% (n = 932) of 
oropharyngeal cancer cases with HPV-positive cancers displaying a lower 
comorbidity burden than HPV-negative cancers. 90% of oral cavity cancer cases 
were managed surgically compared with only 30.6% of oropharyngeal and 29.4% of 
laryngeal cancers (Table 1).  
 
Relationship between covariates, comorbidity and survival 
Univariate analyses showed that all covariates were individually associated with 
comorbidity (Table 2). Participants’ age (χ2 138.4; df(3); p<.001), treatment modality 
(χ2 124.3; df(9); p<.001) and annual household income (χ2 115.1; df(6); p<.001) 
exhibited the strongest statistical evidence of an association with comorbidity burden. 
To explore the relationship further treatment modality was grouped into surgical and 
non-surgical modalities and the highest comorbidity scores (ACE > 1) combined into 
one group. In this analysis observed differences were small (49% of people with ACE 
= 0 had surgery compared to 47% of people with ACE >1) and there was no 
statistical evidence to support an association between surgical treatment and co-
morbidity  (χ2 3.42; df(2); p = .18; Cramer’s V = .04). 
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With the exception of gender, education level and treatment modality, all covariates 
were also individually associated with OS (Supplementary Table 1).  
 
Survival analyses 
In a minimally adjusted Cox regression model comorbidity displayed a dose-
dependent relationship with OS across all three HNC sites (Table 3). After full 
adjustment for demographic, clinical, social and behavioural factors, this trend 
remained strong with HRs of 1.4 (95% CI = 1.1, 1.7), 1.7 (95% CI = 1.3, 2.2) and 2.8 
(95% CI = 1.9, 4.0) for mild, moderate and severe comorbidity, respectively (p-
trend<.001). In unadjusted Kaplan-Meier analyses, participants with oropharyngeal 
and oral cavity cancers who did not have comorbid conditions displayed the best 
survival, while for laryngeal cancers no clear survival benefit between participants 
without comorbidity and those with mild decompensation (Figure 2).  The association 
between survival and comorbidity did not differ between HPV-positive and HPV-
negative oropharyngeal cancers after adjusting for all covariates (Table 3).  
Finally, fully adjusted and stratified survival analyses demonstrated that higher 
comorbidity was associated with worse OS in both people who received surgical 
treatment (HR 1.6, 95% CI = 1.1, 2.2 for mild comorbidity; HR 2.0, 95% CI = 1.4, 2.9 
for moderate/severe comorbidity) and those who were managed with chemoradiation 
or radiotherapy alone (HR 1.3, 95% CI 0.9, 1.7 for mild comorbidity; HR 1.8, 95% CI 
1.3, 2.5 for moderate/severe comorbidity). There was no statistical evidence of a 
difference in the association between co-morbidity and survival in these two 
treatment groups. 
Schoenfeld residuals testing confirmed the validity of the proportional hazards 
assumption for all variables. 
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Discussion 
 
In this large contemporary clinical cohort of people with HNC in the UK we showed a 
dose-response relationship between comorbidity and survival that was consistent 
across tumour sites and independent of adjustment for lifestyle confounding factors. 
The dose-dependent effect of comorbid status on OS (HR 1.5, 95% CI 1.2, 2.0 for 
mild comorbidity; HR 3.8, 95% CI 2.6, 5.4 for severe comorbidity; p-trend<.001) was 
mildly attenuated after full adjustment for all covariates (HR 1.4, 95% CI 1.1, 1.7 for 
mild comorbidity; HR 2.8, 95% CI 1.9, 4.0 for severe comorbidity; p-trend<.001). The 
narrow confidence intervals and the consistency across cancer sites mean our 
findings are unlikely to be the result of chance.  
 
Our findings are consistent with previous studies that identified pre-treatment 
comorbidity as an important independent prognosticator (5-7, 10, 14, 16, 22-25). Only a few 
of these previous studies were able to control for smoking and alcohol intake in their 
analyses (4, 22, 24, 26-28) and none adjusted for socioeconomic variables and health risk 
behaviours in the same model. Most of these studies only included people with 
oropharyngeal cancers (22, 26-28).  
 
One large Canadian cohort study analysed data from medical record review to 
explore the impact of baseline comorbidity on OS across four HNC sub-sites (4). They 
used the claims-based Charlson Comorbidity Index (CCI) (29) to record comorbidity 
data retrospectively. Unlike the ACE 27 (used in our analysis), the CCI does not 
quantify disease severity and includes fewer comorbid conditions. Both indices are 
validated for use in people with cancer but data and results derived from different 
comorbidity indices may differ significantly (15, 28, 30, 31). In the UK, the ACE 27 remains 
the recommended tool for recording comorbidity data in people with cancer (32). They 
reported that higher comorbidity scores were associated with greater all-cause 
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mortality in people with cancers of the oral cavity, larynx and nasopharynx. They 
observed marked attenuation after adjustment for confounders and as a result 
concluded that comorbidity was a surrogate marker for health risk behaviours rather 
than an independent prognostic indicator. The lack of attenuation of the association 
in our data may reflect the more accurate prospective collection of data on co-
morbidity and lifestyle confounders. 
 
In keeping with previous research, our baseline data also showed a lower burden of 
comorbidity and better unadjusted OS in people with HPV-positive oropharyngeal 
cancers compared to HPV-negative cases (4, 12, 13, 16, 22, 23, 33). In HPV-stratified 
analyses the dose-response relationship between comorbidity and survival was less 
pronounced. However, point estimates indicated that greater comorbidity remained 
associated with worse survival, independent of HPV status. Adjustment for potential 
confounders resulted in only a slight attenuation of the effect size in people with 
HPV-positive cancer and did not markedly change the observed association in 
people with HPV-negative cancers.   
 
There is some evidence to suggest that comorbidity at diagnosis may influence 
treatment selection and may constitute an independent risk factor for post-surgical 
outcomes(3, 9, 10, 34) and cause-specific mortality(35, 36) in people with HNC.  However, 
these findings are not consistent throughout the literature with one study failing to 
demonstrate an association between concurrent comorbid conditions and survival in 
treatment-stratified analysis(37). To date no prospective study has examined potential 
differences in baseline comorbidity scores and OS in people treated surgically 
compared to those who underwent conservative management for HNC. In our large 
cohort the distribution of treatment modalities among cancer sub-sites reflects 
current standard of care(38-41). Oral cavity cancers were predominantly managed 
surgically while over two-thirds of oropharyngeal and laryngeal cancers received 
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non-surgical treatment. In univariate analysis treatment modality was independently 
associated with comorbidity. However, the observed differences were modest 
suggesting that comorbid status is not an important determinant of treatment 
selection. When adjusted for potential confounders including cancer site, the OS of 
people who received surgical versus non-surgical treatment were comparable. Our 
robust effect size estimates suggest that comorbidity is an important independent 
predictor of post-treatment survival irrespective of treatment modality.  
 
Implications for practice 
In recent years research suggested that presence of comorbid conditions may have 
a similar prognostic significance to increasing the stage of the cancer (4, 5, 14, 42). Our 
results confirm the importance of comorbidity and support the use of pre-treatment 
comorbidity data as part of a comprehensive prognostic assessment at the time of 
diagnosis. We also demonstrated that treatment selection does not affect the 
prognostic value of comorbidity burden.. In the UK the National Cancer Intelligence 
Network recommends that comorbidity data is collected for all people with cancer 
using the ACE 27 index to optimise pre-operative assessment and risk stratification 
(32). More research is needed to quantify the effect of specific conditions compared to 
total comorbidity burden on treatment outcomes to develop a comprehensive 
prognostic assessment system that combines TNM stage and comorbidity to more 
accurately predict survival in people with HNC. 
 
Strength and limitations 
Our study has a number of strengths. First, this large prospective clinical cohort 
study with a sample size of 2,272 participants allowed us to produce robust effect 
size estimates and stratify by cancer sub-site. Second, we used the ACE 27 to 
document the presence and severity of comorbidity. Third, our analyses accounted 
for a broad range of known confounders in incrementally adjusted regression 
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models. To date no other study on the prognostic impact of comorbidity in HNC sub-
types adjusted for clinical, socioeconomic and behavioural covariates in the same 
model. This study therefore adds significantly to the emerging evidence on the 
importance of comorbidity as an independent prognostic indicator in HNC. 
 
Our study also had some limitations. First, our list of confounding variables was 
extensive but it was not exhaustive. For example, anaemia at diagnosis and 
performance status have been reported as potential predictors of survival in people 
with HNC (6, 9, 16, 35, 43, 44) but were not collected in our study. Types and details of 
comorbid conditions were not recorded. As a result, their distribution, individual 
association with the chosen treatment modality could not be analysed. Second, we 
used self-report from questionnaires to collect information on health behaviours. Self-
report may be unreliable and underestimate current behaviour and not reflect prior or 
subsequent lifestyle behaviour. Reassuringly the proportion of current, former and 
never smokers in this study was similar to that reported in other cohorts (22, 24, 45). So, 
though we adjusted for a wide range of confounders in our models, residual 
confounding by unmeasured or poorly measured factors is still a possibility. Third, 
cause-specific mortality data were not available so we were unable to examine the 
association of comorbidity with specific causes of death. Fourth, despite a mean 
follow-up time of 3.2 years and the large overall sample size, the number of deaths 
and people with severe comorbidities was low in some groups, reducing statistical 
power in stratified analyses.  Finally, only 49.1% of eligible people (n= 5,478 of 
11,158) were enrolled in the study and complete data were only available for less 
than half of all enrolled participants (n= 2,272) limiting generalisability of our findings. 
 
Conclusion  
Our study found that comorbidity at baseline is a strong prognostic indicator of 
survival in a subset of HNCs, independent of health risk behaviours and treatment 
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selection. Our findings support the need for comorbid disease to be included in future 
prognostication models for HNC to further aid treatment planning and to provide 
more accurate survival estimates. 
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Table 1. Distribution of variables by cancer sub-site 
 
Variables All sites 
No. of 
people (%) 
n= 2272 
Oral cavity  
No. of 
people (%) 
n= 668 
Oropharynx  
 
Larynx 
No. of 
people 
(%) n= 
530 
   All cases 
No. of 
people (%) 
n= 1074 
HPV-
negative   
No. of 
people (%) 
n= 254 
HPV-
positive 
No. of 
people (%) 
n= 678 
 
Age, years 
Mean (s.d) 
 
60.8 (10.5) 
 
61.2 (11.9) 
 
58.5 (9.1) 
 
59.3 (9.8) 
 
58.2 (8.7) 
 
65.0 (10.0) 
Gender, n (%) 
Male 
 
1739 (76.5) 
 
423 (63.3) 
 
855 (79.6) 
 
195 (76.8) 
 
547 (80.7) 
 
461 (87.0) 
ACE 27, n (%) 
0 
1 
2 
3 
 
1077 (47.4) 
748 (32.9) 
362 (15.9) 
85 (3.7) 
 
304 (45.5) 
208 (31.1) 
119 (17.8) 
37 (5.5) 
 
564 (52.5) 
346 (32.2) 
138 (12.8) 
26 (2.4) 
 
108 (42.5) 
87 (24.3) 
46 (18.1) 
13 (5.1) 
 
387 (57.1) 
211 (31.1) 
71 (10.5) 
9 (1.3) 
 
209 (39.5) 
194 (36.5) 
105 (19.8) 
22 (4.1) 
TNM stage,  
n (%)  
I/II 
III/IV 
 
 
903 (39.7) 
1369 (60.3) 
 
 
396 (59.3) 
272 (40.7) 
 
 
149 (13.9) 
925 (86.1) 
 
 
63 (24.8) 
191 (75.2) 
 
 
64 (9.4) 
614 (90.6) 
 
 
358 (67.4) 
172 (32.6) 
Treatment,  
n (%) 
Surgery 
Surgery + 
ChemoRT  
RT 
 
 
724 (31.9) 
361 (15.9) 
759 (33.4) 
428 (18.8) 
 
 
499 (74.7) 
102 (15.3) 
35 (5.2) 
32 (4.8) 
 
 
105 (9.8) 
223 (20.8) 
634 (59.0) 
112 (10.4) 
 
 
39 (15.4) 
50 (19.7) 
129 (50.8) 
36 (14.2) 
 
 
49 (7.2) 
152 (22.4) 
420 (62.0) 
57 (8.4) 
 
 
120 (22.6) 
36 (6.8) 
90 (17.1) 
284 (53.5) 
Marital status,  
n (%) 
Single 
In relationship 
Separated or 
widowed 
 
 
275 (12.1) 
1547 (68.1) 
450 (19.8) 
 
 
97 (14.5) 
416 (62.3) 
155 (23.2) 
 
 
115 (10.7) 
780 (72.6) 
179 (16.7) 
 
 
40 (15.8) 
152 (59.8) 
62 (24.4) 
 
 
58 (8.6) 
531 (78.3) 
89 (13.1) 
 
 
63 (11.9) 
351 (66.3) 
116 (21.8) 
Education,  
n (%) 
School 
College 
Degree 
 
 
1036 (45.6) 
806 (35.5) 
430 (18.9) 
 
 
299 (44.8) 
218 (32.6) 
151 (22.6) 
 
 
442 (41.2) 
420 (39.1) 
212 (19.7) 
 
 
109 (42.9) 
101 (39.8) 
44 (17.3) 
 
 
277 (40.9) 
268 (39.5) 
133 (19.6) 
 
 
295 (55.7) 
168 (31.6) 
67 (12.6) 
Annual income 
(£), n (%) 
<18,000 
18,000-34,999 
>35,000 
 
 
1034 (45.5) 
663 (29.2) 
575 (25.3) 
 
 
333 (49.9) 
187 (28.0) 
148 (22.2) 
 
 
394 (36.7) 
333 (31.0) 
347 (32.3) 
 
 
128 (50.4) 
70 (27.6) 
56 (22.1) 
 
 
195 (28.8) 
227 (33.5) 
256 (37.8) 
 
 
307 (58.0) 
143 (26.9) 
80 (15.1) 
Smoking status, 
n (%) 
Never 
Former 
Current 
 
 
530 (23.3) 
1296 (57.0) 
446 (19.6) 
 
 
164 (24.6) 
340 (50.9) 
164 (24.6) 
 
 
321 (29.9) 
584 (54.4) 
169 (15.7) 
 
 
43 (16.9) 
110 (43.3) 
101 (39.8) 
 
 
240 (35.4) 
388 (57.2) 
50 (7.4) 
 
 
45 (8.5) 
373 (70.2) 
113 (21.3) 
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 Abbreviations: ACE 27 = Adult Comorbidity Evaluation 27; HPV = Human Papillomavirus; s.d. = 
standard deviation; TNM = Tumour, node, metastasis; Surgery+ = surgery plus adjunct; ChemoRT = 
chemoradiotherapy; RT = radiotherapy 
Alcohol intake, 
n (%) 
None 
Moderate 
Hazardous 
Harmful 
 
 
598 (26.3) 
477 (21.0) 
862 (37.9) 
335 (14.7) 
 
 
168 (25.1) 
141 (21.1) 
245 (36.7) 
114 (17.1) 
 
 
289 (26.9) 
226 (21.0) 
413 (38.5) 
146 (13.6) 
 
 
65 (25.6) 
42 (16.5) 
88 (34.7) 
59 (23.2) 
 
 
181 (28.2) 
163 (24.0) 
262 (38.6) 
62 (9.1) 
 
 
141 (26.6) 
110 (20.9) 
204 (38.4) 
75 (14.1) 
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Table 2. Univariate analysis of the relationship between comorbidity and all covariates 
 
Variables,   
No. of people (%) 
ACE 27 
score 0 
No. of 
people (%) 
ACE 27  
score 1 
No. of people (%) 
ACE 27 
score 2  
No. of 
people (%) 
ACE 27 
score >2  
No. of 
people (%) 
χ
2
 df p  
Age (years), n (%) 
<65 820 (76.1) 417 (55.8) 180 (49.7) 37 (43.5) 138.
4 
3 <.001 
>65 257 (23.9) 331 (44.3) 182 (50.3) 48 (56.5) 
Gender, n (%) 
Male 799 (74.2) 576 (77.0) 291 (80.4) 73 (76.5) 10.5 3 .015 
Female 278 (25.8) 172 (23.0) 71 (19.6) 12 (23.5) 
Cancer site, n (%) 
Oral cavity 304 (28.2) 208 (27.8) 119 (32.9) 37 (43.5) 40.6 6 <.001 
Oropharynx 564 (52.4) 346 (46.3) 138 (38.1) 26 (30.6) 
     Larynx 209 (19.4) 194 (25.9) 105 (29.0) 22 (25.9) 
TNM Stage, n (%) 
I/II 396 (36.8) 301 (40.2) 173 (47.8) 33 (38.8) 13.9 3 .003 
III/IV 681 (63.2) 447 (59.8) 189 (52.2) 52 (61.2) 
Treatment modality, n (%) 
Surgery  329 (30.6) 240 (32.1) 115 (31.8) 40 (47.1) 124.
3 
9 <.001 
Surgery +  206 (19.1) 99 (13.2) 44 (12.2) 12 (14.1) 
ChemoRT 419 (38.9) 243 (32.5) 86 (23.8) 11 (12.9) 
RT 123 (11.4) 166 (22.2) 117 (32.3) 22 (25.9) 
Marital status, n (%) 
Single 134 (12.4) 74 (9.9) 54 (14.9) 13 (15.3) 32.5 6 <.001 
In relationship 775 (72.0) 497 (66.4) 228 (63.0) 47 (55.3) 
Separated or 
widowed 
168 (15.6) 177 (23.7) 80 (22.1) 25 (29.4) 
Education, n (%) 
School 442 (41.0) 357 (47.7) 197 (54.4) 40 (47.1) 26.2 6 <.001 
College 411 (38.2) 245 (32.8) 117 (32.3) 33 (38.8) 
Degree 224 (20.8) 146 (19.5) 48 (13.3) 12 (14.1) 
Annual income (£), n (%) 
<18,000 382 (35.5) 373 (49.8) 226 (62.4) 53 (62.4) 115.
1 
6 <.001 
18,000-34,999 344 (31.9) 207 (62.4) 92 (25.4) 20 (23.5) 
>35,000 351 (32.6) 168 (62.4)  44 (12.2) 12 (14.1) 
Smoking status, n (%) 
Never 291 (27.0) 162 (21.7) 67 (18.5) 10 (11.8) 28.1 6 <.001 
Former 604 (56.1) 435 (58.2) 206 (56.9) 51 (60.0) 
Current 182 (16.9) 151 (20.2) 89 (25.6) 24 (28.2) 
Alcohol intake, n (%) 
None 242 (22.5) 217 (29.0) 110 (30.4) 29 (34.1) 31.8 9 <.001 
Moderate 251 (23.3) 147 (19.7) 66 (18.2) 13 (15.3) 
Hazardous 440 (40.0) 278 (37.2) 117 (32.3) 27 (31.8) 
Harmful 144 (13.4) 106 (14.2) 69 (19.1) 16 (18.8) 
HPV status (oropharyngeal subgroup only), n (%) 
HPV negative 108 (21.8) 87 (29.2) 46 (39.3) 13 (59.1) 27.8 3 <.001 
HPV positive 387 (78.2) 211 (70.8) 71 (60.7) 9 (40.9) 
Formatted Table
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Abbreviations: ACE 27 = Adult Comorbidity Evaluation 27; df = degrees of freedom; HPV = 
Human Papillomavirus; TNM = Tumour, node, metastasis; surgery+ = surgery plus adjunct; 
ChemoRT = chemoradiotherapy; RT = radiotherapy 
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 Table 3. Association between comorbidity and overall survival, stratified by cancer sub-site and HPV status 
 
Abbreviations: HR = hazard ratio; CI = confidence interval; HPV = Human Papillomavirus 
*Adjusted for age and gender 
†Adjusted for age, gender, cancer site (“All sites” only), TNM stage and treatment modality 
‡ Adjusted for age, gender, cancer site (“All sites” only), TNM stage, treatment modality, marital status, education and annual household income 
Model Comorbidity  All sites Oral cavity Oropharynx Larynx 
    All cases HPV-negative HPV-positive  
  HR 
(95%CI) 
p-trend 
 
HR 
(95%CI) 
p-trend 
 
HR 
(95%CI) 
p-trend 
 
HR 
(95%CI) 
p-
trend 
HR 
(95%CI) 
p-
trend 
HR 
(95% CI) 
p-trend 
 
Minimally adjusted model* 
Minimally 
adjusted* 
Mild 1.5 (1.2, 2.0) <.001 1.5 (1.0, 2.2) <.001 1.8 (1.3-2.6) <.001 2.2 (1.2, 
3.6) 
.02 1.1 
(0.6-
2.0) 
.05 1.2 (0.8, 1.9) .003 
Moderate 2.0 (1.5, 2.6) 1.8 (1.1, 2.7) 2.5 (1.6, 3.7) 2.0 (1.1, 
3.7) 
2.0 (1.1, 
3.8) 
1.8 (1.1, 2.9) 
Severe 3.8 (2.6, 5.4) 4.6 (2.8, 7.6) 3.3 (1.6, 6.7) 2.6 (1.3, 5.5) 
Clinical model † 
Clinical 
model† 
Mild 1.5 (1.2, 1.9) <.001 1.3 (0.9, 2.0) <.001 1.8 (1.2, 2.5) <.001 1.8 (1.0, 
3.2) 
.03 1.2 (0.7, 
2.0) 
.02 1.4 (0.9, 2.1) .003 
Moderate 1.9 (1.5, 2.5) 1.4 (0.9, 2.2) 2.4 (1.6, 3.7) 1.7 (0.9, 
3.3) 
2.4 (1.2, 
4.5) 
2.0 (1.2, 3.3) 
Severe 3.3 (2.3. 4.8) 3.5 (2.1, 5.8) 3.3 (1.6, 6.9) 2.2 (1.0, 4.6) 
Social model ‡  
Social model 
‡  
Mild 1.4 (1.1, 1.8) <.001 1.3 (0.9, 2.0) .001 1.6 (1.1, 2.3) <.001 1.7 (0.9, 
2.0) 
.11 1.1 (0.6, 
2.0) 
.03 1.3 (0.8, 2.0) .004 
Moderate 1.8 (1.4, 2.3) 1.3 (0.8, 2.0) 2.1 (1.4, 3.3) 1.6 (0.9, 
3.2) 
2.3 (1.2, 
4.3) 
2.0 (1.2, 3.4) 
Severe 3.0 (2.0, 4.3) 3.0 (1.8, 5.1) 3.0 (1.4, 6.1) 2.2 (1.0, 4.7) 
Behavioural model § 
Behavioural§ 
Mild 1.4 (1.1, 1.7) <.001 1.3 (0.9, 1.9) .001 1.6 (1.1, 2.4) <.001 1.8 (0.9, 
3.3) 
.08 1.2 (0.7, 
2.1) 
.03 1.3 (0.8, 2.0) .006 
Moderate 1.7 (1.3, 2.2) 1.2 (0.8, 1.9) 2.1 (1.3, 3.2) 2.0 (1.0, 
3.8) 
2.4 (1.2, 
4.6) 
2.0 (1.2, 3.4) 
Severe 2.8 (1.9, 4.0) 2.7 (1.6, 4.6) 3.2 (1.5, 6.8) 2.2 (1.0, 4.8) 
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§Adjusted for age, gender, cancer site (“All sites” only), TNM stage, treatment modality, marital status, education, household income per .annump.a, smoking 
and alcohol intake 
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Table 4: Association between comorbidity and survival, stratified by treatment modality 
 
 
Abbreviations: HR = hazard ratio; CI = confidence interval 
*Adjusted for age and gender 
†Adjusted for age, gender, cancer site and TNM stage 
‡ Adjusted for age, gender, cancer site, TNM stage, marital status, education and annual household income 
§Adjusted for age, gender, cancer site, TNM stage, marital status, education, household income per annum, smoking and alcohol intake 
 
Model Comorbidity Surgical treatment Non-surgical treatment 
  HR (95% CI) p-trend HR (95% CI) p-trend 
Minimally adjusted* Mild  1.8 (1.3-2.5) <.001 1.3 (1.0-1.8) <.001 
Moderate/ Severe 2.5 (1.7-3.5) 2.3 (1.7-3.2) 
Clinical† Mild  1.6 (1.2-2.3) <.001 1.4 (1.5-1.9) <.001 
Moderate/ Severe 2.3 (1.6-3.2) 2.1 (1.5-3.0) 
Social‡ Mild  1.6 (1.2-2.3) <.001 1.3 (0.9-1.8) <.001 
Moderate/ Severe 2.1 (1.5-2.9) 1.9 (1.4-2.7) 
Behavioural§ Mild  1.6 (1.1-2.2) <.001 1.3 (0.9-1.7) <.001 
Moderate/ Severe 2.0 (1.4-2.9) 1.8 (1.3-2.5) 
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Supplementary table 1. Univariate analysis of the relationship between survival and all 
covariates 
Variables Alive 
No. of people (%) 
Dead 
No. of people (%) 
χ
2
 df p 
Age (years), n (%) 
<65 1200 (66.5) 254 (54.5) 22.9 1 <.001 
>65 606 (33.6) 212 (45.5) 
Gender, n (%) 
Male 1373 (76.0) 366 (78.5) 1.3 1 .253 
Female 433 (24.0) 100 (21.5) 
Cancer site, n (%)      
Oral cavity 496 (27.5) 172 (36.9) 23.4 2 <.001 
Oropharynx 898 (49.7) 176 (37.8) 
Larynx 412 (22.8) 118 (25.3) 
TNM Stage, n (%) 
I/II 756 (41.9) 147 (31.6) 16.5 1 <.001 
III/IV 1050 (38.1) 319 (68.5) 
Treatment modality, n (%) 
Surgery  578 (32.0) 146 (31.3) 6.0 3 .11 
Surgery +  287 (15.9) 74 (15.9) 
ChemoRT 618 (34.2) 141 (30.3) 
RT 323 (17.9) 105 (22.5) 
Marital status, n (%) 
Single 208 (11.5) 67 (14.4) 25.8 2 <.001 
In relationship 1274 (70.5) 273 (58.6) 
Separated or widowed 324 (17.9) 126 (27.0) 
Education, n (%) 
School 803 (44.5) 233 (50.0) 5.4 2 .069 
College 660 (36.5) 146 (31.3) 
Degree 343 (19.0) 87 (28.7) 
Annual income (£), n (%) 
<18,000 756 (41.9) 278 (59.7) 50.8 2 <.001 
18,000-34,999 549 (30.4) 114 (24.5) 
>35,000 501 (27.7) 74 (15.9) 
Comorbidity, n (%) 
None 947 (51.3) 150 (32.2) 93.7 3 <.001 
Mild  583 (32.3) 165 (35.4) 
Moderate  253 (14.0) 109 (23.4) 
Severe  43 (2.4) 42 (9.0) 
Smoking status, n (%) 
Never 463 (25.6) 67 (14.4) 46.1 2 <.001 
Former 1041 (57.6) 255 (54.7) 
Current 302 (16.7) 144 (30.9) 
Alcohol intake, n (%) 
None 478 (26.5) 120 (25.8) 12.6 3 .006 
Moderate 401 (22.2) 76 (16.3) 
Hazardous 679 (37.6) 183 (39.3) 
Harmful 248 (13.7) 87 (18.7) 
HPV status (oropharyngeal subgroup only), n (%) 
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Abbreviations: df = degrees of freedom; HPV = Human Papillomavirus; TNM = Tumour, node, 
metastasis; surgery+ = surgery plus adjunct; ChemoRT = chemoradiotherapy; RT= radiotherapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HPV negative 179 (22.8) 75 (51.0) 49.7 1 <.001 
HPV positive 606 (77.2) 72 (49.0) 
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Flowchart of participant inclusion criteria  
 
254x190mm (72 x 72 DPI)  
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Unadjusted Kaplan-Meier plots for overall survival by cancer subsites  
 
67x47mm (300 x 300 DPI)  
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